Researchers find method that could resurrect an abandoned pancreatic cancer targeted drug

Pancreatic cancer is on track to become the second leading cause of cancer-related deaths by 2020. These statistics are due, in part, to pancreatic cancer's resistance to most targeted cancer therapies. Working with pancreatic cancer cells, researchers have now found a mechanism that could be responsible for the cancer's resistance to at least one targeted approach. If the results hold true in animal models and eventually clinical trials, the approach could help researchers develop more effective combination therapies and breathe new life into forgotten and failed cancer drugs.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Cancer is a leading cause of death throughout the world, and cancer therapy remains a big medical challenge in terms of both its therapeutic efficacy and safety. Therefore, to find out a safe anticancer drug has been long goal for oncologist and medical scientists. Among clinically used medicines with no or little toxicity, fenofibrate is a drug of the fibrate class that plays an important role in lowering the levels of serum cholesterol and triglycerides while elevating the levels of high-density lipoproteins. Recently, several studies have implied that fenofibrate may exert anticancer effects via a variety of pathways in...
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Conclusion: The co-delivery of Gem and miR-21i using Au DENPs can be significantly promoted by UTMD technology, hence providing a promising strategy for effective pancreatic cancer treatments.
Source: Theranostics - Category: Molecular Biology Authors: Tags: Research Paper Source Type: research
Introduction: Hyperglycaemia is a significant cause of morbidity in cancer patients accounting for up to 5% of emergency oncology admissions (1). The incidence of hyperglycaemia in non-diabetic patients receiving anti-cancer therapy has been shown to be as high as 11.6% (2). One significant factor is the high doses of steroids administered either as part of the systemic anti-cancer treatment to control nausea and vomiting, or to palliate other cancer-related symptoms such as pain or anorexia. Patients with gastro-intestinal (GI) malignancies, in particular, often receive high doses of steroids as part of their chemotherapy...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Introduction: Gastro-intestinal cancer (GI) include a variety of cancers that affect esophagus, gallbladder, liver, pancreas, stomach, intestine and other organs involved in digestive system. The above types of cancers appear higher mortality rates in comparison with cancers in other systems. Therefore, it is essential the optimization of treatment management. Even though great achievements have been performed the last years in prediction of cancer therapy, treatment is based in specific markers, avoiding genes that affect or affected through signaling transduction pathways. The present study aimed to analyze the gene expr...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Objectives Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumor entities. The identification of distinct PDAC subtypes with a similar genetic background had given a first impression that probably epigenetic alterations promote tumor cell heterogeneity. Epigenetic modifications, such as histone modifications, are reversible and therefore attractive targets for cancer therapy.
Source: Pancreatology - Category: Gastroenterology Authors: Tags: 9. Experimental pancreatic cancer I Source Type: research
RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds and others. Get the full story at our sister site, Drug Delivery Business News. The post RenovoRx raises $7m for drug-device pancreatic cancer therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Funding Roundup Oncology Pharmaceuticals Regulatory/Compliance Vascular RenovoRx Source Type: news
Conclusion: PRIT allows the specific delivery of highly cytotoxic payload to tumor site competing with the conventional directly labeled antibody conjugate but results in reduced dose to normal tissue and decreased hematotoxicity. This study confirms the clinical relevance of 225Ac-PRIT.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Preclinical Probes for Oncology II Source Type: research
Cancers, Vol. 10, Pages 142: A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology Cancers doi: 10.3390/cancers10050142 Authors: Robert Van Sciver Michael Lee Caroline Lee Alex Lafever Elizaveta Svyatova Kevin Kanda Amber Colliver Lauren Siewertsz van Reesema Angela Tang-Tan Vasilena Zheleva Monicah Bwayi Minglei Bian Rebecca Schmidt Lynn Matrisian Gloria Petersen Amy Tang Oncogenic K-RAS mutations are found in virtually all pancreatic cancers...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In conclusion, we discovered that electroporation can enhance the cytotoxic effect of cisplatin in pancreatic cancer cells in vitro. This effect was evident for cells from the primary culture. The obtained results confirm the importance of primary cells models in studies on the efficacy of experimental cancer therapies. PMID: 29750170 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
In conclusion, the present results demonstrated that under hypoxic conditions, OBX combined with a small dose of GEM may be able to inhibit the growth, migration and invasion of pancreatic cancer cells, possibly via inhibition of EMT process. These results may provide a promising strategy for pancreatic cancer therapy. PMID: 29749486 [PubMed - as supplied by publisher]
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Pancreas | Pancreatic Cancer | Science | Statistics